Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.19019
M. Khyatti
The Objectives: Cancer development and/or progression can be imputed to telomere shortening or lengthening. The cur-rent research was planned to assess the relation between leucocyte telomere length (LTL) and nasopharyngeal carcinoma (NPC) development, and to evaluate the association between this biomarker and patients' clinical outcomes, mainly response to chemo-radiotherapy, survival and EBV-DNA load. Methods: Leucocyte telomere length was measured using a singleplex quantitative polymerase chain reaction (qPCR) method in 104 NPC patients and 52 healthy controls. The association between LTL and NPC development was assessed using a Khi-deux test. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated by conditional logistic regression to evaluate the relationship LTL and patient’s characteristics. The correlation between LTL and 4-years patient’s survival outcomes was assessed by Kaplan–Meier and Cox-regression analyses. Results: Data analysis revealed a significant association between LTL and risk of NPC development (p<0.0001). LTL was also significantly associated with gender (p=0.003), cigarette smoking (p=0.02) and pre-EBV-DNA load (p=0.017) in NPC. However, no significant association was obtained between LTL and age, alcohol consumption, TNM classification, disease stage, response to chemo-radiotherapy and survival outcomes of NPC patients (p>0.05). Conclusion: The study finding highlighted the close association between LTL and NPC development and showed a significant association with gender, cigarette smoking and pre-EBV-DNA load, suggesting that LTL could be a promising biomarker for better management of NPC in Morocco. Nevertheless, more studies are needed to highlight the value of LTL as a biomarker for the prediction of the response to treatment and prognosis of NPC.
{"title":"Association of Leucocyte Telomere Length with Nasopharyngeal Carcinoma Risk and Prognosis","authors":"M. Khyatti","doi":"10.14744/ejmo.2023.19019","DOIUrl":"https://doi.org/10.14744/ejmo.2023.19019","url":null,"abstract":"The Objectives: Cancer development and/or progression can be imputed to telomere shortening or lengthening. The cur-rent research was planned to assess the relation between leucocyte telomere length (LTL) and nasopharyngeal carcinoma (NPC) development, and to evaluate the association between this biomarker and patients' clinical outcomes, mainly response to chemo-radiotherapy, survival and EBV-DNA load. Methods: Leucocyte telomere length was measured using a singleplex quantitative polymerase chain reaction (qPCR) method in 104 NPC patients and 52 healthy controls. The association between LTL and NPC development was assessed using a Khi-deux test. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated by conditional logistic regression to evaluate the relationship LTL and patient’s characteristics. The correlation between LTL and 4-years patient’s survival outcomes was assessed by Kaplan–Meier and Cox-regression analyses. Results: Data analysis revealed a significant association between LTL and risk of NPC development (p<0.0001). LTL was also significantly associated with gender (p=0.003), cigarette smoking (p=0.02) and pre-EBV-DNA load (p=0.017) in NPC. However, no significant association was obtained between LTL and age, alcohol consumption, TNM classification, disease stage, response to chemo-radiotherapy and survival outcomes of NPC patients (p>0.05). Conclusion: The study finding highlighted the close association between LTL and NPC development and showed a significant association with gender, cigarette smoking and pre-EBV-DNA load, suggesting that LTL could be a promising biomarker for better management of NPC in Morocco. Nevertheless, more studies are needed to highlight the value of LTL as a biomarker for the prediction of the response to treatment and prognosis of NPC.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"98 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74562637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.38141
Liang Han
,
{"title":"Association of Serum Interleukin-6 and Interleukin-8 Levels with Clinical Benefit from Immune Checkpoint Inhibitors in Patients with Advanced Gastric Cancer","authors":"Liang Han","doi":"10.14744/ejmo.2023.38141","DOIUrl":"https://doi.org/10.14744/ejmo.2023.38141","url":null,"abstract":",","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135103374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.18762
Jia-Yong Su
Objectives: Future pandemics involving COVID-19 or other respiratory disorders may pose risks to treatment outcomes among cancer patients on chemotherapy. Here we explored whether diagnosis with COVID-19 might influence how chemotherapy alters the peripheral hemogram of cancer patients. To examine changes in the peripheral hemo-gram before and after chemotherapy depending on whether patients were unexposed to the SARS-CoV-2 virus, had COVID-19, or were recovering from COVID-19. Methods: We retrospectively reviewed the records of 8,900 patients with solid cancers who underwent chemotherapy between October 10, 2022 and March 1, 2023. We compared hemograms before and after chemotherapy within and across the following three groups: 3,215 patients previously unexposed to SARS-CoV-2, 2,771 patients with COVID-19, and 2,817 patients recovering from COVID-19. We compared counts of white blood cells, red blood cells, and platelets as well as percentages of neutrophils between the first blood sampling after admission and the first sampling after conclusion of chemotherapy. Results: Of the various parameters examined, only the changes in counts of white blood cells and platelets differed significantly across the three patient groups. White blood cell count before chemotherapy was lower in patients with COVID-19 than in those unexposed to the virus or those recovering from COVID-19. Platelet count after chemotherapy was lower in patients with COVID-19 than in those recovering from COVID-19. Chemotherapy reduced the red blood cell count and increased the neutrophil percentage in all three patient groups, with the largest changes occurring in patients with COVID-19; however, these changes did not achieve statistical significance. Conclusion: These studies suggest that COVID-19 does not significantly alter the peripheral hemogram of cancer patients who receive effective chemotherapy.
{"title":"Association of COVID-19 with Features of the Peripheral Hemogram Among Cancer Patients Undergoing Chemotherapy","authors":"Jia-Yong Su","doi":"10.14744/ejmo.2023.18762","DOIUrl":"https://doi.org/10.14744/ejmo.2023.18762","url":null,"abstract":"Objectives: Future pandemics involving COVID-19 or other respiratory disorders may pose risks to treatment outcomes among cancer patients on chemotherapy. Here we explored whether diagnosis with COVID-19 might influence how chemotherapy alters the peripheral hemogram of cancer patients. To examine changes in the peripheral hemo-gram before and after chemotherapy depending on whether patients were unexposed to the SARS-CoV-2 virus, had COVID-19, or were recovering from COVID-19. Methods: We retrospectively reviewed the records of 8,900 patients with solid cancers who underwent chemotherapy between October 10, 2022 and March 1, 2023. We compared hemograms before and after chemotherapy within and across the following three groups: 3,215 patients previously unexposed to SARS-CoV-2, 2,771 patients with COVID-19, and 2,817 patients recovering from COVID-19. We compared counts of white blood cells, red blood cells, and platelets as well as percentages of neutrophils between the first blood sampling after admission and the first sampling after conclusion of chemotherapy. Results: Of the various parameters examined, only the changes in counts of white blood cells and platelets differed significantly across the three patient groups. White blood cell count before chemotherapy was lower in patients with COVID-19 than in those unexposed to the virus or those recovering from COVID-19. Platelet count after chemotherapy was lower in patients with COVID-19 than in those recovering from COVID-19. Chemotherapy reduced the red blood cell count and increased the neutrophil percentage in all three patient groups, with the largest changes occurring in patients with COVID-19; however, these changes did not achieve statistical significance. Conclusion: These studies suggest that COVID-19 does not significantly alter the peripheral hemogram of cancer patients who receive effective chemotherapy.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135103897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.61594
F. Ari
.
．
{"title":"Investigation of Anti-Cancer Activity of Newly Synthesized 2,4-pentadien-1-one Derivative Containing Benzofuran in Human Lung and Colon Cancer Cells","authors":"F. Ari","doi":"10.14744/ejmo.2023.61594","DOIUrl":"https://doi.org/10.14744/ejmo.2023.61594","url":null,"abstract":".","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87447333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.59207
K. Bliznakova
,
，
{"title":"Clinical Assessment of CoLumbo Deep Learning System for Central Canal Stenosis Diagnostics","authors":"K. Bliznakova","doi":"10.14744/ejmo.2023.59207","DOIUrl":"https://doi.org/10.14744/ejmo.2023.59207","url":null,"abstract":",","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88320178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.45210
Zhen Feng
KIF9, KIF11, KIF14, and KIF18A) were generally higher in LIHC compared to normal tissues. The expression levels of KIF11 and KIF14 showed a significant correlation with the prognosis of LIHC. KIF11 and KIF14 may serve as potential biomarkers for LIHC. Conclusion: The study provides insights into the roles of KIF family members in LIHC. Identifies potential biomarkers (KIF11 and KIF14) and therapeutic targets for the clinical treatment of liver cancer. Further experimental validation is required to confirm these findings.
{"title":"Potential Value of the Motor Protein Family KIF as a Diagnostic & Prognostic Marker for Human Hepatocellular Carcinoma: A Prospective Research","authors":"Zhen Feng","doi":"10.14744/ejmo.2023.45210","DOIUrl":"https://doi.org/10.14744/ejmo.2023.45210","url":null,"abstract":"KIF9, KIF11, KIF14, and KIF18A) were generally higher in LIHC compared to normal tissues. The expression levels of KIF11 and KIF14 showed a significant correlation with the prognosis of LIHC. KIF11 and KIF14 may serve as potential biomarkers for LIHC. Conclusion: The study provides insights into the roles of KIF family members in LIHC. Identifies potential biomarkers (KIF11 and KIF14) and therapeutic targets for the clinical treatment of liver cancer. Further experimental validation is required to confirm these findings.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"73 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135103873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.61011
M. Sankaran
Objectives: The primary target of this study is to explore a novel therapeutic pathway of nano Diosgenin (DG) by pin-pointing the metabolic enzymes that underlies its anti-breast cancer impacts. Methods: A single dosage of 7.12 Dimethyl Benz(a)anthracene (DMBA) (25 mg/kg b.wt) was injected to induce breast cancer. Oral administration of DG (10 mg/kg b.wt) and DG encapsulated chitosan nanoparticle (DG@CS-NP) (5 mg/kg b.wt) was used to medicate DMBA induced tumor bearing rats just after the emergence of a tumor. After the experimental period, biochemical analyses were carried out. Results: Mammary carcinoma bearing rats showed a significant rise in the levels of glycolytic enzymes (hexokinase, phosphoglucoisomerase, and aldolase) and the pentose phosphate pathway enzyme (glucose-6-phosphate dehydrogenase). It also elicits a drop in gluconeogenic enzymes (glucose-6-phosphatase and fructose 1, 6- diphosphatase) and mitochondrial enzymes (succinate dehydrogenase and malate dehydrogenase). Contrarily, nano DG dramatically reverted the rates of glycolytic enzymes, pentose phosphate pathway enzymes, gluconeogenic enzymes, and mitochondrial enzymes in the mammary, liver and kidney tissues to near normal tiers on compared to plain DG treated rats. Thereby, confirming its chemotherapeutic prospects on metabolic rewiring. Conclusion: Thus, our observations suggested that nano DG is a potent therapeutic agent that might have a significant influence on metabolic complications of breast cancer than free DG.
{"title":"Therapeutic impact of Nano diosgenin on metabolic reprogramming in an animal model of mammary oncogenesis via modulating carbohydrate metabolizing enzymes","authors":"M. Sankaran","doi":"10.14744/ejmo.2023.61011","DOIUrl":"https://doi.org/10.14744/ejmo.2023.61011","url":null,"abstract":"Objectives: The primary target of this study is to explore a novel therapeutic pathway of nano Diosgenin (DG) by pin-pointing the metabolic enzymes that underlies its anti-breast cancer impacts. Methods: A single dosage of 7.12 Dimethyl Benz(a)anthracene (DMBA) (25 mg/kg b.wt) was injected to induce breast cancer. Oral administration of DG (10 mg/kg b.wt) and DG encapsulated chitosan nanoparticle (DG@CS-NP) (5 mg/kg b.wt) was used to medicate DMBA induced tumor bearing rats just after the emergence of a tumor. After the experimental period, biochemical analyses were carried out. Results: Mammary carcinoma bearing rats showed a significant rise in the levels of glycolytic enzymes (hexokinase, phosphoglucoisomerase, and aldolase) and the pentose phosphate pathway enzyme (glucose-6-phosphate dehydrogenase). It also elicits a drop in gluconeogenic enzymes (glucose-6-phosphatase and fructose 1, 6- diphosphatase) and mitochondrial enzymes (succinate dehydrogenase and malate dehydrogenase). Contrarily, nano DG dramatically reverted the rates of glycolytic enzymes, pentose phosphate pathway enzymes, gluconeogenic enzymes, and mitochondrial enzymes in the mammary, liver and kidney tissues to near normal tiers on compared to plain DG treated rats. Thereby, confirming its chemotherapeutic prospects on metabolic rewiring. Conclusion: Thus, our observations suggested that nano DG is a potent therapeutic agent that might have a significant influence on metabolic complications of breast cancer than free DG.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84272333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.26480
: M1 Macrophage cells are a part of the immune system, which are also involved in tumor microenvironment (TME). Specific macrophages are activated by different chemokines like IL-4, IL-13 and IFN-γ and subsequently are able to differentiate into M1 and M2. Moreover, Ms2 are divided into 4 sub-phenotypes: M2a, M2b, M2c and M2d. We have analysed the relationship between macrophages, the role of micro RNAs and their importance in angiogenesis and lymphangiogenesis. Furthermore, we investigated how macrophages interact in the pathogenesis of breast, gastric and colorectal cancer. We reported several studies regarding the involvement of these cells in tumoral angiogenesis and proliferation. This review represents a starting point to better comprehend the molecular and biological steps regarding the involvement of Ms in cancer, focusing the attention on their effects in specific tumors.
{"title":"Macrophages in Tumor Microenvironment: From Molecular Aspects to Clinical Applications","authors":"","doi":"10.14744/ejmo.2023.26480","DOIUrl":"https://doi.org/10.14744/ejmo.2023.26480","url":null,"abstract":": M1 Macrophage cells are a part of the immune system, which are also involved in tumor microenvironment (TME). Specific macrophages are activated by different chemokines like IL-4, IL-13 and IFN-γ and subsequently are able to differentiate into M1 and M2. Moreover, Ms2 are divided into 4 sub-phenotypes: M2a, M2b, M2c and M2d. We have analysed the relationship between macrophages, the role of micro RNAs and their importance in angiogenesis and lymphangiogenesis. Furthermore, we investigated how macrophages interact in the pathogenesis of breast, gastric and colorectal cancer. We reported several studies regarding the involvement of these cells in tumoral angiogenesis and proliferation. This review represents a starting point to better comprehend the molecular and biological steps regarding the involvement of Ms in cancer, focusing the attention on their effects in specific tumors.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135103868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.64688
Serkan Guven
Objectives: Primary central nervous system lymphoma (PCNSL) is a rare malignant disease with poor prognosis. Its low incidence leads to challenges in decision-making for treatment. As a matter of fact, there is still no consensus on the appropriate treatment modalities. In this context, the objective of this study is to investigate and comparatively assess the efficacies of several treatment modalities in the treatment of PCNSL. Methods: Thirty-four patients diagnosed with PCNSL at 5 different hematology centers between 2007 and 2021 were included in the study. Patients’ data from all five centers were collected retrospectively. Since ibrutinib is not approved for this indication in Turkey, consent for off-label use of ibrutinib is obtained from each patient. Ethics committee ap- proval was obtained on June 9, 2021 with decision number 2021/18-05. Results: The median age of the patients was 59 (min.: 22, max.: 78) years. The male-to-female ratio was 1.26/1. Nineteen (55.9%) patients had Eastern Cooperative Oncology Group (ECOG) performance score of ≥2. Fifteen (44.1%) patients had normal lactate dehydrogenase (LDH) levels and only 14.7% of the patients had B symptoms at the time of diagnosis. Magnetic resonance imaging (MRI) revealed a single mass lesion in 14 (41.2%) patients. As an induction therapy, meth-otrexate-based regimen was administered in 29 (85.3%) patients. Only 14 of the 34 patients received 4 or more cycles of high-dose methotrexate (MTX). About 32.4% of the patients received radiation therapy (RT) during follow-up as a part of induction therapy. Five patients received only RT due to poor performance status. Ibrutinib was administered in 5 patients for refractory disease. It was determined that four or more cycles of MTX treatment increased progression-free survival (PFS) (p=0.031) and overall survival (OS) (p=0.012). Moreover, RT improved PFS (p=0.023). Considering that the complete response achieved by induction therapy influences long-term survival, achievement of the best response to the treatment regimens administered in combination with new agents may prolong survival (PFS: p=0.01, OS: p=0.023). Conclusion: The findings of this study indicate that the initial response to treatment is crucial. Additionally, it was found that high-dose MTX treatment should be administered for 4 cycles or more in order to achieve the best results. Furthermore, it was determined that ibrutinib monotherapy was well-tolerated in our patients with relapsed/refractory disease, with excellent clinical benefits. In conclusion, a combination therapy consisting of high-dose MTX, ibrutinib, and rituximab appears to be a promising initial treatment approach in appropriate patients.
{"title":"Clinical Outcomes and Treatment Patterns of Primary Central Nervous System Lymphoma: Multicenter Retrospective Analysis","authors":"Serkan Guven","doi":"10.14744/ejmo.2023.64688","DOIUrl":"https://doi.org/10.14744/ejmo.2023.64688","url":null,"abstract":"Objectives: Primary central nervous system lymphoma (PCNSL) is a rare malignant disease with poor prognosis. Its low incidence leads to challenges in decision-making for treatment. As a matter of fact, there is still no consensus on the appropriate treatment modalities. In this context, the objective of this study is to investigate and comparatively assess the efficacies of several treatment modalities in the treatment of PCNSL. Methods: Thirty-four patients diagnosed with PCNSL at 5 different hematology centers between 2007 and 2021 were included in the study. Patients’ data from all five centers were collected retrospectively. Since ibrutinib is not approved for this indication in Turkey, consent for off-label use of ibrutinib is obtained from each patient. Ethics committee ap- proval was obtained on June 9, 2021 with decision number 2021/18-05. Results: The median age of the patients was 59 (min.: 22, max.: 78) years. The male-to-female ratio was 1.26/1. Nineteen (55.9%) patients had Eastern Cooperative Oncology Group (ECOG) performance score of ≥2. Fifteen (44.1%) patients had normal lactate dehydrogenase (LDH) levels and only 14.7% of the patients had B symptoms at the time of diagnosis. Magnetic resonance imaging (MRI) revealed a single mass lesion in 14 (41.2%) patients. As an induction therapy, meth-otrexate-based regimen was administered in 29 (85.3%) patients. Only 14 of the 34 patients received 4 or more cycles of high-dose methotrexate (MTX). About 32.4% of the patients received radiation therapy (RT) during follow-up as a part of induction therapy. Five patients received only RT due to poor performance status. Ibrutinib was administered in 5 patients for refractory disease. It was determined that four or more cycles of MTX treatment increased progression-free survival (PFS) (p=0.031) and overall survival (OS) (p=0.012). Moreover, RT improved PFS (p=0.023). Considering that the complete response achieved by induction therapy influences long-term survival, achievement of the best response to the treatment regimens administered in combination with new agents may prolong survival (PFS: p=0.01, OS: p=0.023). Conclusion: The findings of this study indicate that the initial response to treatment is crucial. Additionally, it was found that high-dose MTX treatment should be administered for 4 cycles or more in order to achieve the best results. Furthermore, it was determined that ibrutinib monotherapy was well-tolerated in our patients with relapsed/refractory disease, with excellent clinical benefits. In conclusion, a combination therapy consisting of high-dose MTX, ibrutinib, and rituximab appears to be a promising initial treatment approach in appropriate patients.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"82 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78446214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.41377
Ying Ji, Yandan Xie, Ming Zhang, Jie Zhou, L. Peng, Ying-ru Zheng, S. Shu
,
，
{"title":"Role of SATB2 5' Untranslated Region Promoter Methylation in Formation of Non-syndromic Cleft Palate Only","authors":"Ying Ji, Yandan Xie, Ming Zhang, Jie Zhou, L. Peng, Ying-ru Zheng, S. Shu","doi":"10.14744/ejmo.2023.41377","DOIUrl":"https://doi.org/10.14744/ejmo.2023.41377","url":null,"abstract":",","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85173666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：